Brought to you by 
Arrowhead, Janssen pen deal worth up to $3.7bn
28 Sep 2021
Executive Summary
In a deal potentially worth $3.7bn, Arrowhead Pharmaceuticals Inc. licensed Janssen Pharmaceuticals Inc. exclusive worldwide rights to develop and commercialize its ARO-HBV program. In addition, Janssen has the exclusive option to select up to three targets outside of Arrowhead’s current pipeline.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
-
Biotechnology
- Antisense, Oligonucleotides
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Arrowhead, Janssen pen deal worth up to $3.7bn
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice